Xarelto on prevention of stroke and noncentral nervous system systemic embolism in treatment-naïve Asian patients with non-valvular atrial fibrillation (XaMINA)
The purpose of the study is to collect additional information of Xarelto treatment in routine clinical practice. Patients affected by atrial fibrillation and who will get Xarelto as a prophylactic treatment against stroke and systemic embolism (Stroke Prevention in Atrial Fibrillation) will be observed.
- Female and male patients aged 19 years or older (Korea) and aged 20 years or older (Taiwan) - Diagnosis of NVAF - Patients for whom the decision to initiate treatment with rivaroxaban is made as per physician’s routine treatment practice - Treatment naïve regarding stroke prevention for atrial fibrillation - Signed informed consent
- Contraindications for rivaroxaban according to the local market authorization/summary of product characteristics (SmPC) - Patients participating in an investigational program with interventions outside of routine clinical practice
Xarelto® on prevention of stroke and noncentral nervous system systeMIc embolism in treatment Naïve Asian patients with non-valvular atrial fibrillation